(R)-(-)-2-吡咯酮-5-甲酸甲酯 | 64700-65-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-(-)-2-吡咯酮-5-甲酸甲酯
• 中文别名: (R)-2-吡咯烷酮-5-甲酸甲酯
• 英文名称: methyl (2R)-pyroglutamate
• 英文别名: (R)-methyl 5-oxopyrrolidine-2-carboxylate；methyl (R)-5-oxopyrrolidine-2-carboxylate；methyl (R)-pyroglutamate；D-pyroglutamic acid methyl ester；D-methyl pyroglutamate；(R)-5-oxo-pyrrolidine-2-carboxylic acid methyl ester；methyl (2R)-5-oxopyrrolidine-2-carboxylate；methyl D-pyroglutamate
• CAS: 64700-65-8
• 化学式: C₆H₉NO₃
• 分子量: 143.142
• InChiKey: HQGPKMSGXAUKHT-SCSAIBSYSA-N

物化性质

• 沸点：
  83℃/0.25mm
• 密度：
  1.226
• 溶解度：
  溶于二氯甲烷

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl (r)-(-)-2-pyrrolidinone-5-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl (r)-(-)-2-pyrrolidinone-5-carboxylate
CAS number: 64700-65-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9NO3
Molecular weight: 143.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-(-)-2-吡咯酮-5-甲酸甲酯 在 铂 sodium tetrahydroborate 、 氧气 、 碳酸氢钠 作用下， 以 乙醇 、 水 为溶剂， 反应 6.0h， 生成 D-焦谷氨酸
  参考文献：
  名称：

  Saijo, Shigeyoshi; Wada, Masao; Himizu, Jun-ichi, Chemical and pharmaceutical bulletin, 1980, vol. 28, # 5, p. 1449 - 1458

  摘要：

  DOI：
• 作为产物：
  描述：

  D-焦谷氨酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 以75%的产率得到(R)-(-)-2-吡咯酮-5-甲酸甲酯
  参考文献：
  名称：

  (1R,5S)-(−)-6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE. HIGHLY ENANTIOSELECTIVE INTRAMOLECULAR CYCLOPROPANATION CATALYZED BY DIRHODIUM(II) TETRAKIS[METHYL 2-PYRROLIDONE-5(R)-CARBOXYLATE]

  摘要：

  DOI：

  10.15227/orgsyn.073.0013

文献信息

• [EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015246A1

  公开（公告）日：2014-01-23

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  披露的是通过给予公式(I)化合物的组合物和方法来治疗骨质疏松症、骨折、骨丢失以及增加骨密度，其中组合物包含公式(I)的化合物和药用可接受的载体，其中L1、L2、L4、R1、R4、R5、R6和s按说明书定义。
• [EN] LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS<br/>[FR] COMPOSÉS LACTAMES EN TANT QU'AGONISTES SÉLECTIFS DU RÉCEPTEUR EP4 POUR L'UTILISATION DANS LE TRAITEMENT DE MALADIES ET D'ÉTATS À MÉDIATION PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014144610A1

  公开（公告）日：2014-09-18

  Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

  披露了公式(I)的化合物，其中L1、L2、L3、R1、R4、R5和R6如说明书定义。公式(I)的化合物是EP4激动剂，可用于治疗青光眼、骨质疏松症、骨折、牙周骨丢失、骨科植入物、脱发、神经性疼痛及相关疾病。还描述了药物组合物和治疗条件或疾病的方法。
• LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
  申请人：CAYMAN CHEMICAL COMPANY, INC.

  公开号：US20160060216A1

  公开（公告）日：2016-03-03

  Disclosed herein are compounds of formula (I) wherein L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification. Compounds of formula (I) are EP 4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

  披露了公式(I)的化合物 其中L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 ，和s如说明书所定义。 公式(I)的化合物是EP 4 激动剂，用于治疗青光眼、骨质疏松症、骨折、牙周骨丢失、矫形植入物、脱发、神经性疼痛和相关的疾病。 还描述了药物组合物和治疗条件或疾病的方法。
• Stereocontrolled Total Synthesis of (−)-Kaitocephalin
  作者：Rishi G. Vaswani、A. Richard Chamberlin

  DOI：10.1021/jo702329z

  日期：2008.3.1

  scalable synthetic route profits from the strategic utilization of substrate-controlled manipulations for the iterative installation of the requisite stereogenic centers. The key transformations include a diastereoselective modified Claisen condensation, a chemo- and diastereoselective reduction of a β-keto ester, and the substrate-directed hydrogenation of a dehydroamino ester derivative. During the course

  本文描述了基于吡咯烷的生物碱 (-)-kaitocephalin 的全化学合成的立体控制策略的成功实施。这种可扩展的合成路线得益于对底物控制操作的战略利用，以迭代安装必要的立体中心。关键转化包括非对映选择性修饰的克莱森缩合、β-酮酯的化学和非对映选择性还原以及脱氢氨基酯衍生物的底物导向氢化。在我们的研究过程中，发现了一个有趣的立体收敛环化反应，用于高效组装 kaitocephalin 2,2,5-三取代的吡咯烷核心。
• Synthesis of a beta-turn forming depsipeptide for hydrogen bond mediated electron transfer studies
  作者：David A. Williamson、Bruce E. Bowler

  DOI：10.1016/0040-4020(96)00743-0

  日期：1996.9

  Hydrogen bonds are believed to play an important role in the mediation of electron transfer processes in proteins. A porphyrin/depsipeptide/p-benzoquinone molecule has been synthesized to help understand this role of hydrogen bond mediated electron transfer in proteins. The synthesis, room temperature folding conformation, and steady-state electron transfer are described.

  据信氢键在蛋白质中电子转移过程的介导中起重要作用。已经合成了卟啉/二肽/对苯醌分子，以帮助理解蛋白质中氢键介导的电子转移的这种作用。描述了合成，室温折叠构象和稳态电子转移。